Alessio Cantore

Alessio Cantore

Auto-generated profile, based on publicly available information

Alessio Cantore

San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2007 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
BBBrian D Brown
Brian D Brown
BGBernhard Gentner
Bernhard Gentner
ACAlessio Cantore
Alessio Cantore
SCSilvia Colleoni
Silvia Colleoni
MAMario Amendola
Mario Amendola
LNLuigi Naldini
Luigi Naldini

21 August 2011 in Nature Methods
Verified
Journal Article
Closed access
PDF file
ALAngelo Lombardo
Angelo Lombardo
DCDaniela Cesana
Daniela Cesana
PGPietro Genovese
Pietro Genovese
BSBruno Di Stefano
Bruno Di Stefano
EPElena Provasi
Elena Provasi
LNLuigi Naldini
Luigi Naldini

2 October 2019 in Nature
Verified
Journal Article
Closed access
PDF file
ABAlexandre P. Bénéchet
Alexandre P. Bénéchet
GSGiorgia De Simone
Giorgia De Simone
PLPietro Di Lucia
Pietro Di Lucia
FCFrancesco Cilenti
Francesco Cilenti
GBGiulia Barbiera
Giulia Barbiera
MIMatteo Iannacone
Matteo Iannacone

15 December 2007 in Blood
Verified
Journal Article
Closed access
PDF file
BBBrian D. Brown
Brian D. Brown
ACAlessio Cantore
Alessio Cantore
AAAndrea Annoni
Andrea Annoni
LSLucia Sergi Sergi
Lucia Sergi Sergi
ALAngelo Lombardo
Angelo Lombardo
LNLuigi Naldini
Luigi Naldini
A longstanding goal for the treatment of hemophilia B is the development of a gene transfer strategy that can maintain sustained production of clotting factor IX (F.IX) in the absence of an immune response. To this end, we have sought to use lentiviral vectors (LVs) as a means for systemic gene transfer. Unfortunately, initial evaluation of LVs expressing F.IX from hepatocyte-specific promoters failed to achieve sustained F.IX expression in hemophilia B mice due to the induction of an anti-F.IX cellular immune response. Further analysis suggested that this may be a result of off-target transgene expression in hematopoietic-lineage cells of the spleen. In order to overcome this problem, we modified our vector to contain a target sequence for the hematopoietic-specific microRNA, miR-142-3p. This eliminated off-target expression in hematopoietic cells, and enabled sustained gene transfer in hemophilia B mice for more than 280 days after injection. Treated mice had more than 10% normal F.IX activity, no detectable anti-F.IX antibodies, and were unresponsive to F.IX immunization. Importantly, the mice survived tail-clip challenge, thus demonstrating phenotypic correction of their bleeding diathesis. This work, which is among the first applications to exploit the microRNA regulatory pathway, provides the basis for a promising new therapy for the treatment of hemophilia B.

4 March 2015 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
ACAlessio Cantore
Alessio Cantore
MRMarco Ranzani
Marco Ranzani
CBCynthia C. Bartholomae
Cynthia C. Bartholomae
MVMonica Volpin
Monica Volpin
PVPatrizia Della Valle
Patrizia Della Valle
LNLuigi Naldini
Luigi Naldini
Gene therapy with lentiviral vectors targeting transgene expression to hepatocytes provides stable reconstitution of clotting activity in dogs with hemophilia B and does not show genotoxicity in tumor-prone mice.

22 May 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
MMMichela Milani
Michela Milani
AAAndrea Annoni
Andrea Annoni
FMFederica Moalli
Federica Moalli
TLTongyao Liu
Tongyao Liu
DCDaniela Cesana
Daniela Cesana
LNLuigi Naldini
Luigi Naldini
Lentiviral vectors with high surface content of CD47 improved gene transfer efficiency to hepatocytes in nonhuman primates.